Schwab Charles Investment Management Inc. boosted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 460,869 shares of the biopharmaceutical company’s stock after purchasing an additional 16,183 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 1.03% of Vanda Pharmaceuticals worth $7,513,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Vanda Pharmaceuticals by 26.4% during the 1st quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after acquiring an additional 521,669 shares during the period. Point72 Asset Management L.P. boosted its position in Vanda Pharmaceuticals by 1,544.3% during the 1st quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after acquiring an additional 2,333,400 shares during the period. FMR LLC raised its stake in shares of Vanda Pharmaceuticals by 60.7% in the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Vanda Pharmaceuticals by 65.3% in the 1st quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after buying an additional 370,900 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Vanda Pharmaceuticals by 0.8% in the 1st quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock worth $8,600,000 after buying an additional 4,700 shares in the last quarter. Institutional investors own 86.49% of the company’s stock.
WARNING: This report was posted by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/vanda-pharmaceuticals-inc-vnda-position-lifted-by-schwab-charles-investment-management-inc/1697914.html.
VNDA has been the topic of a number of research reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Vanda Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $21.29.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 16.15 on Tuesday. Vanda Pharmaceuticals Inc. has a 52 week low of $12.70 and a 52 week high of $18.99. The stock’s market cap is $724.46 million. The firm has a 50-day moving average price of $17.51 and a 200-day moving average price of $15.66.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same quarter in the prior year, the business posted $0.01 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. On average, equities research analysts predict that Vanda Pharmaceuticals Inc. will post ($0.43) EPS for the current year.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.